Skip Navigation


Annals of Oncology Advance Access originally published online on October 17, 2007
Annals of Oncology 2008 19(2):242-246; doi:10.1093/annonc/mdm457
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/2/242    most recent
mdm457v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Song, E.-K.
Right arrow Articles by Heo, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Song, E.-K.
Right arrow Articles by Heo, D. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

hematologic malignancies

Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma

E.-K. Song1,4, S.-Y. Kim1, T. M. Kim1, K.-W. Lee1, T. Yun1, I.-I. Na1, H. Shin1, S. H. Lee1, D. W. Kim1, S. I. Khwarg2 and D. S. Heo1,3,*

1 Department of Internal Medicine
2 Department of Ophthalmology
3 Cancer Research Institute, Seoul National University College of Medicine, Seoul
4 Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea

* Correspondence to: Dr D. S. Heo, Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea. Tel: +82-2-2072-2857; Fax: +82-2-742-6689; E-mail: heo1013{at}snu.ac.kr

Background: Radiotherapy is commonly used as a first-line treatment for localized ocular adnexal extranodal marginal zone B-cell lymphoma (EMZBL), despite its ophthalmologic complications. This study was undertaken to analyze the efficacy of first-line chemotherapy in treating EMZBL. Chemotherapy was followed by radiotherapy only in recurrent cases.

Patients and methods: Twenty-one patients with histologically confirmed EMZBL were treated with combination of cyclophosphamide, vincristine, and prednisolone (CVP). Radiotherapy was given to CVP failure cases.

Results: CVP alone resulted in overall response rate of 100% [complete remission (CR), 76.2%]. After a median follow-up of 58 months, 14 (66.7%) of 21 cases were disease free with CVP alone, while seven cases showed disease progression, including two extra-orbital and five local failures. Radiotherapy was delivered to five local failure cases, who subsequently achieved CR with late ophthalmologic complications. There were tolerable adverse events associated with CVP.

Conclusions: Front-line CVP, in conjunction with radiotherapy in recurrent cases, is effective and well tolerated in patients with localized ocular adnexal EMZBL.

Key words: chemotherapy, MALT lymphoma, ocular adnexal lymphoma

Received for publication July 4, 2007. Revision received August 16, 2007. Accepted for publication August 20, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

in this issue

Ann Oncol 2008 19: 199. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 BloodHome page
A. Stefanovic and I. S. Lossos
Extranodal marginal zone lymphoma of the ocular adnexa
Blood, July 16, 2009; 114(3): 501 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Esmaeli, P. McLaughlin, B. Pro, F. Samaniego, I. Gayed, F. Hagemeister, J. Romaguera, F. Cabanillas, S. S. Neelapu, R. Banay, et al.
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma
Ann. Onc., April 1, 2009; 20(4): 709 - 714.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.